Validation of the EGS usercode DOSE3D for internal beta dose calculation at the cellular and tissue levels.

Internal radiotherapy is currently focusing on beta emitters such as 90Y or 131I because of their high-energy emissions. However, conventional dosimetric methods (MIRD) are known to be limited for such applications. They are unable to take into account microscopic radionuclide distribution because standardized anthropomorphic phantoms are used, and absorbed dose is calculated at the organ level. New tools are therefore required for dose assessment at cellular and tissue level (10-100 microm). The purpose of this study was to validate, at this scale, a Monte Carlo usercode (DOSE3D), based on the MORSE combinatorial geometry package and the EGS code system. Dose point-kernel calculations in water were compared to those published by Cross et al and Simpkin and Mackie. They confirm that DOSE3D is a reliable tool for cellular dosimetry in various geometric configurations.

[1]  D. R. Anderson,et al.  Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. , 1999, International journal of oncology.

[2]  J. Gillis,et al.  Methods in Computational Physics , 1964 .

[3]  J L Humm,et al.  Estimate of absorbed dose based on two-dimensional autoradiographic information in internal radionuclide therapy. , 2001, Medical physics.

[4]  W G Cross,et al.  Beta-ray dose distributions from point sources in an infinite water medium. , 1992, Health physics.

[5]  H. Atkins,et al.  Assessment of thyroid function and anatomy with technetium-99m as pertechnetate. , 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  M Berman,et al.  A schema for absorbed-dose calculations for biologically-distributed radionuclides. , 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  A. Kassis.  The MIRD approach: remembering the limitations. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  D. Fisher.  Radiation dosimetry for radioimmunotherapy. An overview of current capabilities and limitations , 1994, Cancer.

[9]  J L Humm,et al.  Image analysis for the study of radionuclide distribution in tissue sections. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  David W. O. Rogers,et al.  Presta: The parameter reduced electron-step transport algorithm for electron monte carlo transport , 1986 .

[11]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Walter R. Nelson,et al.  Geometry Methods and Packages , 1988 .

[13]  L. Gordon,et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[15]  I Clairand,et al.  DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A L Boyer,et al.  Validation of a dose-point kernel convolution technique for internal dosimetry , 1995, Physics in medicine and biology.

[17]  P Andreo,et al.  Constraints of the multiple-scattering theory of Molière in Monte Carlo simulations of the transport of charged particles. , 1993, Medical physics.

[18]  M H Loew,et al.  Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy. , 1998, Medical physics.

[19]  H. Paul.  Shapes of beta spectra , 1966 .

[20]  R. Toohey,et al.  Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  David W. O. Rogers,et al.  A Comparison of EGS and ETRAN , 1988 .

[22]  Stephen M. Seltzer,et al.  An Overview of ETRAN Monte Carlo Methods , 1988 .

[23]  P. Zanzonico,et al.  Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  D. Goldenberg.  Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  G. A. Bruno,et al.  Retention of 113mIn-59Fe-ferric hydroxide in the mouse. , 1971, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  C S Chui,et al.  A Monte Carlo approach to patient-specific dosimetry. , 1996, Medical physics.

[27]  L. M. Cobb,et al.  Internal dosimetry using data derived from autoradiographs. , 1993, Journal of Nuclear Medicine.

[28]  W E Bolch,et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  E. Yorke,et al.  Treatment planning for radio-immunotherapy. , 1996, Physics in medicine and biology.

[30]  T. Mackie,et al.  EGS4 Monte Carlo determination of the beta dose kernel in water. , 1990, Medical physics.

[31]  P. Mountford.  Internal dosimetry: developments and limitations , 1996, European Journal of Nuclear Medicine.

[32]  I. Kawrakow.  Accurate condensed history Monte Carlo simulation of electron transport. I. EGSnrc, the new EGS4 version. , 2000, Medical physics.

[33]  R K Ten Haken,et al.  Three‐dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose‐rate nonuniformity , 1994, Cancer.

[34]  Klemens Scheidhauer,et al.  Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  L. Gordon,et al.  Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.